Shannon Zumbaugh, MBA on LinkedIn: Labcorp will be participating in the 9th Annual CAR-TCR Summit this… (2024)

Labcorp helped accelerate a biotech sponsor's novel CAR T-cell cancer therapies by 6-12 months using deep cell therapy expertise. Learn how our integrated preclinical, clinical and lab services resulted in an optimized preclinical program, data-driven trials and seamless COVID-19 pivots: https://lnkd.in/gn4uv5Yx#CellandGeneTherapy #CellTherapy #CARTCell #ClinicalDevelopment

15

Labcorp teams across the U.S. and U.K. collaborated to support an emerging biotech company's gene therapy for a rare neurodegenerative disorder. Our capabilities in toxicology, biodistribution, CMC and biomarkers enabled the biotech’s successful investigational new drug application and advancements in the clinic. Read the case study to learn more: https://lnkd.in/gmnxVg6Q#CellandGeneTherapy #GeneTherapy #AAV #NeurodegenerativeDiseases

9

Join our growing team in Greenfield Indiana.

10

At Labcorp, we're using flow cytometry testing to detect patient immune responses to CAR T-cell cancer therapy. Unlike traditional ELISA methods, this approach analyzes antibodies against the full CAR protein in its native membrane environment, providing a more valid immunogenicity assessment to support treatment safety and efficacy. Read our scientific poster to learn how Labcorp is advancing CAR T-cell therapy: https://lnkd.in/gDkSapuQ#FlowCytometry #AntidrugAntibodies #CellTherapy #CellandGeneTherapy

8

Discover the latest cell therapy research that could significantly advance targeted cancer therapies in the future. A new approach from Labcorp and xcellbio mimics the tumor microenvironment and leads to more effective T-cell populations. Using the AVATAR System, the research demonstrates improved performance of CAR T-cells cultured in specialized conditions compared to those grown conventionally. Read the full research article: https://lnkd.in/gAq5YSky#CART #CellTherapy #CancerTreatment

10

The CD63 Basophil Panel-1 assay activates basophils to quantify immune engagement and measure CD63, a marker of basophil activation. Read our scientific poster to see how our sensitive flow cytometry method assesses drug effects on basophils, helping optimize dosing and demonstrate efficacy in multi-centric clinical trials: https://lnkd.in/gjsb-dmr#FlowCytometry #Basophils

10

In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/g5WfaQeQ

19

At Labcorp, we share your goal of unlocking the full potential of adoptive cell therapies to treat cancer and autoimmune disorders. Our 22-biomarker flow cytometry panel analyzes infused cell therapies over time, identifying key traits like proliferation capacity that lead to better persistence and clinical outcomes. Discover more in our scientific poster: https://lnkd.in/gqZ-HKh5#FlowCytometry #AdoptiveCellTherapy #ACT #CellandGeneTherapy

11

Quantifying minimal residual disease (MRD) is becoming more important to predict outcomes in chronic lymphocytic leukemia (CLL). Using a combination of antibodies, Labcorp’s flow cytometry assay can accurately detect minimal amounts of CLL cells in patients, without being impacted by the presence of Rituximab in samples. Learn more in our scientific poster:https://lnkd.in/g3JRQsNb#FlowCytometry #ChronicLymphocyticLeukemia #MRD

12